AS MUCH AS 6 MONTHS OF BENEFIT AFTER A SINGLE TREATMENT*
RAPID THERAPEUTIC ONSET
70%
of patients showed
clinically meaningful
improvement by
week 4*
of patients showed
clinically meaningful
improvement by
week 4*
DURABLE THERAPEUTIC RESPONSE
100%
of patients showed
clinically meaningful
improvement by
week 24*
of patients showed
clinically meaningful
improvement by
week 24*
BROAD PATIENT APPLICABILITY
*Based on LANTERN Phase 2 data with 7500 mcg dose, measured with SNOT-22.
The 22-item Sino-Nasal Outcome Test (SNOT-22) is a validated clinical score ranging from 0 to 110 and includes 22 items assessing symptoms and symptom impact associated with CRS. The meaningful clinically important difference is -8.9.
SNOT: Hopkins C et al. Clin. Otolaryngol. 2009, 34, 447-454
